These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3344 related items for PubMed ID: 27169467

  • 1. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ, Gong J, Hatch MM, Nguyen V, Hughes CC, Hutchins JT, Freimark BD.
    Breast Cancer Res; 2016 May 11; 18(1):50. PubMed ID: 27169467
    [Abstract] [Full Text] [Related]

  • 2. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
    Kurozumi S, Fujii T, Matsumoto H, Inoue K, Kurosumi M, Horiguchi J, Kuwano H.
    Med Mol Morphol; 2017 Dec 11; 50(4):185-194. PubMed ID: 28936553
    [Abstract] [Full Text] [Related]

  • 3. Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.
    Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS.
    Cancer Immunol Res; 2017 Oct 11; 5(10):871-884. PubMed ID: 28848054
    [Abstract] [Full Text] [Related]

  • 4. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG.
    J Immunother Cancer; 2019 Feb 08; 7(1):37. PubMed ID: 30736857
    [Abstract] [Full Text] [Related]

  • 5. Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
    Kasikara C, Davra V, Calianese D, Geng K, Spires TE, Quigley M, Wichroski M, Sriram G, Suarez-Lopez L, Yaffe MB, Kotenko SV, De Lorenzo MS, Birge RB.
    Cancer Res; 2019 May 15; 79(10):2669-2683. PubMed ID: 30877108
    [Abstract] [Full Text] [Related]

  • 6. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H, Cimino-Mathews A, Chaher N, Qualls C, Joste N, Colpaert C, Marotti JD, Foisey M, Prossnitz ER, Emens LA, Fiering S.
    Breast Cancer Res Treat; 2018 Sep 15; 171(2):273-282. PubMed ID: 29858752
    [Abstract] [Full Text] [Related]

  • 7. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
    Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.
    Clin Cancer Res; 2016 Mar 15; 22(6):1499-509. PubMed ID: 26515496
    [Abstract] [Full Text] [Related]

  • 8. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B, Pommey S, Smyth MJ, Stagg J.
    Clin Cancer Res; 2013 Oct 15; 19(20):5626-35. PubMed ID: 23983257
    [Abstract] [Full Text] [Related]

  • 9. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM, Hrytsenko O, Quinton T, Berinstein NL, Stanford MM, Mansour M.
    J Immunother Cancer; 2016 Oct 15; 4():68. PubMed ID: 27777777
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL, Page DB.
    Clin Adv Hematol Oncol; 2016 Nov 15; 14(11):922-933. PubMed ID: 27930644
    [Abstract] [Full Text] [Related]

  • 11. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
    Ma YF, Chen C, Li D, Liu M, Lv ZW, Ji Y, Xu J.
    Oncotarget; 2017 Jan 31; 8(5):7614-7624. PubMed ID: 27935862
    [Abstract] [Full Text] [Related]

  • 12. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N, Azuma M, Ikarashi M, Yamamoto M, Sato M, Watanabe KI, Yamashiro K, Takahashi M.
    Breast Cancer; 2018 Jan 31; 25(1):34-42. PubMed ID: 28488168
    [Abstract] [Full Text] [Related]

  • 13. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
    Li Q, Wang Y, Jia W, Deng H, Li G, Deng W, Chen J, Kim BYS, Jiang W, Liu Q, Liu J.
    Clin Cancer Res; 2020 Apr 01; 26(7):1712-1724. PubMed ID: 31848190
    [Abstract] [Full Text] [Related]

  • 14. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S, Passariello M, Agnello L, Esposito S, Collina F, Cantile M, Di Bonito M, Ulasov IV, Fedele M, Zannetti A, De Lorenzo C, Cerchia L.
    J Exp Clin Cancer Res; 2020 Sep 07; 39(1):180. PubMed ID: 32892748
    [Abstract] [Full Text] [Related]

  • 15. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
    Lussier DM, O'Neill L, Nieves LM, McAfee MS, Holechek SA, Collins AW, Dickman P, Jacobsen J, Hingorani P, Blattman JN.
    J Immunother; 2015 Apr 07; 38(3):96-106. PubMed ID: 25751499
    [Abstract] [Full Text] [Related]

  • 16. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, Pan Q, IJzermans JNM, Bruno MJ, Kwekkeboom J.
    Gastroenterology; 2017 Oct 07; 153(4):1107-1119.e10. PubMed ID: 28648905
    [Abstract] [Full Text] [Related]

  • 17. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ, Fox BA.
    Clin Cancer Res; 2017 Oct 15; 23(20):6165-6177. PubMed ID: 28855348
    [Abstract] [Full Text] [Related]

  • 18. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MC.
    Clin Cancer Res; 2017 Jul 15; 23(14):3711-3720. PubMed ID: 28167507
    [Abstract] [Full Text] [Related]

  • 19. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
    Qin G, Wang X, Ye S, Li Y, Chen M, Wang S, Qin T, Zhang C, Li Y, Long Q, Hu H, Shi D, Li J, Zhang K, Zhai Q, Tang Y, Kang T, Lan P, Xie F, Lu J, Deng W.
    Nat Commun; 2020 Apr 03; 11(1):1669. PubMed ID: 32245950
    [Abstract] [Full Text] [Related]

  • 20. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y, Lu F, Fei Q, Yu X, Xiong P, Yu X, Dang Y, Hou Z, Lin W, Lin X, Zhang Z, Pan M, Huang H.
    J Hematol Oncol; 2019 Nov 27; 12(1):124. PubMed ID: 31771616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 168.